Document is current

Article History

Received: 18 November 2022

Accepted: 5 June 2023

First Online: 4 July 2023

Declarations

:

: Not applicable

: Not required. This article does not contain any studies with human participants performed by any of the authors.

: FB has received compensation for consultancy and speaker related activities from Zambon, UCB, Chiesi Pharma, Lundbeck, Sunovion, Bial, SynAgile, Biogen, Kiowa, and Impax. AA has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche, and Medscape; he receives research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020—Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, and Cariparo Foundation. He serves as consultant for Boehringer–Ingelheim for legal cases on pathological gambling. AF is/has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boehringer Ingelheim, Lundbeck, Janssen, Viatris, Otsuka, Recordati, Sonofi, Aventis, and Sunovion. LFS has received speaker fees from Jazz Pharma, Lundbeck, Angelini, Valeas, Bioprojet, Fidia, and Idorsia and has served on scientific advisory boards for Jazz Pharma, Italfarmaco, Bioprojet, Bayer, and Idorsia. CM received funds from the following companies: Novo-nordisk, Angelini, Lundbeck, Roche, Biogen as consultant in scientific board and congress speaker. PB, GB, SS, and AP declare no competing interests.